57536-91-1

Usage

Uses

Used in Pharmaceutical Industry:
1-(2-NAPHTHYL)PIPERAZINE is used as a key intermediate in the synthesis of various pharmaceutical drugs due to its unique chemical structure and properties. Its potential antidepressant, anxiolytic, and antipsychotic properties make it a valuable compound in the development of new medications for mental health treatment.
Used in Research Applications:
As a serotonin receptor agonist, 1-(2-NAPHTHYL)PIPERAZINE is utilized in research to study the effects and mechanisms of action of serotonin in the central nervous system. This helps in understanding the role of serotonin in mood regulation and the development of related therapeutic agents.
Used in Metal Complexes:
1-(2-NAPHTHYL)PIPERAZINE has been investigated for its potential as a ligand for metal complexes, which can be used in various applications such as catalysis, materials science, and medicinal chemistry. Its ability to form stable complexes with metals enhances its utility in these fields.
Used in Organic Synthesis:
1-(2-NAPHTHYL)PIPERAZINE serves as an intermediate in the synthesis of various heterocyclic compounds, which are important in the development of new organic molecules with potential applications in pharmaceuticals, agrochemicals, and other industries. Its presence in these compounds contributes to their unique properties and reactivity.

Upstream product

• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 
• 612-52-2 2-naphthylamine hydrochloride 
• 91-59-8 naphthalen-2-ylamine 
• 554-68-7 triethylamine hydrochloride 
• 111-42-2 2,2'-iminobis[ethanol] 
• 580-13-2 2-bromonaphthalene 
• 684249-11-4 1,1-dimethylethyl 4-(2-naphthalenyl)-1-piperazinecarboxylate 
• 110-85-0 piperazine 
• 43204-63-3 bis(2-bromoethyl)amine hydrobromide 

Downstream Products

• 78091-27-7 4-(4-Naphthalen-2-yl-piperazin-1-yl)-pyridin-3-ylamine 
• 1061517-30-3 C₃₄H₃₄N₄O₂ 
• 1061517-33-6 C₃₂H₂₇F₃N₄O₂ 
• 1061517-34-7 C₃₃H₂₉F₃N₄O₂ 
• 1061517-37-0 C₃₃H₃₀N₄O₃ 
• 1061517-42-7 C₃₂H₂₉FN₄O₂ 
• 1061517-44-9 C₃₂H₂₈F₂N₄O₂ 

Relevant academic research and scientific papers

Electrophilic Zinc Homoenolates: Synthesis of Cyclopropylamines from Cyclopropanols and Amines

Metal homoenolates, produced via C-C bond cleavage of cyclopropanols, have been extensively investigated as nucleophiles for the synthesis of β-substituted carbonyl derivatives. Herein, we demonstrate that zinc homoenolates can react as carbonyl-electrophiles in the presence of nucleophilic amines to yield highly valuable trans-cyclopropylamines in good yields and high diastereoselectivities. GSK2879552, a lysine demethylase 1 inhibitor currently in clinical trials for the treatment of small cell lung carcinoma, was synthesized using this strategy.

Chrysin-piperazine conjugates as antioxidant and anticancer agents

Synthesis of 7-(4-bromobutoxy)-5-hydroxy-2-phenyl-4H-chromen-4-one intermediate treating chrysin with 1,4-dibromobutane facilitated combination of chrysin with a wide range of piperazine moieties which were equipped via reacting the corresponding amines with bis(2-chloroethyl)amine hydrochloride in diethylene glycol monomethyl ether solvent. Free radical scavenging potential of prepared products was analyzed in vitro adopting DPPH and ABTS bioassay in addition to the evaluation of in vitro anticancer efficacies against cervical cancer cell lines (HeLa and CaSki) and an ovarian cancer cell line SK-OV-3 using SRB assay. Bearable toxicity of 7a-w was examined employing Madin-Darby canine kidney (MDCK) cell line. In addition, cytotoxic nature of the presented compounds was inspected utilizing Human bone marrow derived mesenchymal stem cells (hBM-MSCs). Overall, 7a-w indicated remarkable antioxidant power in scavenging DPPH+ and ABTS++, particularly analogs 7f, 7j, 7k, 7l, 7n, 7q, 7v, 7w have shown promising free radical scavenging activity. Analogs 7j and 7o are identified to be highly active candidates against HeLa and CaSki cell lines, whereas 7h and 7l along with 7j proved to be very sensitive towards ovarian cancer cell line SKOV-3. None of the newly prepared scaffolds showed cytotoxic nature toward hBM-MSCs cells. From the structure-activity point of view, nature and position of the electron withdrawing and electron donating functional groups on the piperazine core may contribute to the anticipated antioxidant and anticancer action. Different spectroscopic techniques (FT-IR, 1H NMR, 13C NMR, Mass) and elemental analysis (CHN) were utilized to confirm the desired structure of final compounds.

FATTY ACID SYNTHASE INHIBITORS

Disclosed are compounds having Formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, Y, m, and n are defined herein and methods of using the same.

Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl) ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: Potent in vivo activity in Parkinson's disease anima

Here we report structure - activity relationship study of a novel hybrid series of compounds where structural alteration of aromatic hydrophobic moieties connected to the piperazine ring and bioisosteric replacement of the aromatic tetralin moieties were

Discovery of imidazole carboxamides as potent and selective CCK1R agonists

High-throughput screening revealed diaryl pyrazole 3 as a selective albeit modest cholecystokinin 1 receptor (CCK1R) agonist. SAR studies led to the discovery and optimization of a novel class of 1,2-diaryl imidazole carboxamides. Compound 44, which was profiled extensively, showed good in vivo mouse gallbladder emptying (mGBE) and lean mouse overnight food intake (ONFI) reduction activities.

Parallel synthesis of N-arylpiperazines using polymer-assisted reactions

A series of N-arylpiperazines were prepared in a parallel fashion using palladium-catalyzed cross-coupling, or nucleophilic aromatic displacement chemistries, and polymer-assisted sequestration and purification techniques as key steps.

1-(2-NAPHTHYL) AND 1-(2-AZANAPHTHYL)-4-(1-PHENYLMETHYL)PIPERAZINES BEING DOPAMINE D 4? RECEPTOR SUBTYPE LIGANDS

Disclosed are compounds of formula: (I) or pharmaceutically acceptable addition salts thereof, wherein: X, Y and Z are the same or different and represent optionally substituted carbon or nitrogen; R1 and R2 independently represent organic or inorganic substituents; R3 and R4 are variables independently representing inorganic or organic substituents; A represents C1-C4 alkylene; and R5, R6 and R7 independently represent hydrogen or C1-C6 alkyl, which compounds bind selectively with high affinity to the dopamine D4 receptor subtype and are therefore of use in treatment of various neuropsychological disorders.

A general and convenient synthesis of N-aryl piperazines

A general and convenient synthesis of N-aryl piperazines from bis(2-chloroethyl)amine hydrochloride and a broad range of anilines in diethylene glycol monomethyl ether is described.

SUBSTITUTED PIPERAZINES, (1,4) DIASZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS

The present invention relates to novel piperazine and azepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurodegenerative disorders including Alzheimer's disease.

New μ-opioid receptor agonists with piperazine moiety

New μ-opioid receptor (MOR) agonists containing piperazine and homopiperazine moieties in the structures were synthesized and their affinities to and agonist potencies on MOR were evaluated. Among the synthesized compounds, 4-[4-(2-methoxyphenyl)piperazin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide (20Aa) showed the highest affinity to the human MOR expressed in Chinese hamster ovary (CHO)-K1 cells, and the highest agonist potency on the MOR in isolated guinea-pig ileum preparation.